Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.ipca.com | |
Market Cap | 31,414.92 Cr. | |
Enterprise Value(EV) | 32,869.15 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 22.24 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 55.67 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 251.13 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.93 | Calculated using Price: 1,238.25 |
Dividend Yield | 0.32 | Period Ending 2023-03 |
No. of Shares Subscribed | 25.37 Cr. | 253,704,218 Shares |
FaceValue | 1 | |
About Ipca Laboratories Ltd. | ||
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. Ipca Laboratories is one of the largest suppliers of these APIs worldwide with manufacturing leadership in many APIs globally. It has various APIs and formulations manufacturing facility across the globe. The company has leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India |
1 Day |
|
+3.49% |
1 Week |
|
+6.70% |
1 Month |
|
+3.84% |
3 Month |
|
+17.15% |
6 Month |
|
+34.39% |
1 Year |
|
+56.98% |
2 Year |
|
+24.78% |
5 Year |
|
+168.69% |
10 Year |
|
+200.96% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 12.43 | 4.31 | 8.25 | 9.31 | 15.22 | 17.92 | 27.63 | 17.92 | 8.7 | |
Return on Capital Employed (%) | 13.78 | 4.82 | 9.18 | 9.81 | 16.48 | 19.71 | 30.92 | 20.46 | 11.71 | |
Return on Assets (%) | 7.38 | 2.5 | 4.96 | 5.93 | 10.21 | 12.31 | 20.29 | 13.31 | 6.06 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 2,208 | 2,259 | 2,455 | 2,689 | 3,122 | 3,627 | 4,702 | 5,465 | 5,842 | 6,149 | |
Non Curr. Liab. | 700 | 663 | 548 | 419 | 313 | 290 | 190 | 614 | 902 | 1,127 | |
Curr. Liab. | 904 | 970 | 956 | 1,008 | 1,098 | 1,326 | 1,161 | 1,466 | 1,806 | 2,686 | |
Minority Int. | 16 | 14 | 15 | 77 | 73 | 1,412 | |||||
Equity & Liab. | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,374 | |
Non Curr. Assets | 2,198 | 2,270 | 2,218 | 2,170 | 2,171 | 2,402 | 2,629 | 3,164 | 3,434 | 5,655 | |
Curr. Assets | 1,614 | 1,622 | 1,742 | 1,945 | 2,378 | 2,856 | 3,437 | 4,447 | 5,189 | 5,720 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,374 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,186 | |
Other Income | 59 | 41 | 55 | 58 | 75 | 87 | 129 | 122 | 152 | 142 | |
Total Income | 3,203 | 2,908 | 3,211 | 3,316 | 3,820 | 4,706 | 5,524 | 5,918 | 6,356 | 7,328 | |
Total Expenditure | -2,630 | -2,593 | -2,741 | -2,816 | -3,067 | -3,729 | -3,914 | -4,539 | -5,301 | -6,045 | |
PBIDT | 573 | 314 | 470 | 500 | 753 | 977 | 1,610 | 1,379 | 1,055 | 1,284 | |
Interest | -32 | -35 | -27 | -28 | -22 | -20 | -12 | -11 | -48 | -127 | |
Depreciation | -180 | -163 | -173 | -178 | -182 | -211 | -209 | -232 | -262 | -329 | |
Taxation | -102 | -20 | -68 | -51 | -104 | -135 | -240 | -225 | -253 | -288 | |
Exceptional Items | 68 | ||||||||||
PAT | 259 | 96 | 195 | 239 | 442 | 604 | 1,149 | 911 | 492 | 607 | |
Minority Interest | 3 | 3 | -1 | -6 | -8 | -35 | |||||
Share Associate | -5 | -3 | -8 | -21 | -13 | -8 | |||||
Other Related Items | |||||||||||
Consolidated Net Profit | 254 | 93 | 195 | 239 | 446 | 606 | 1,140 | 884 | 471 | 564 | |
Adjusted EPS | 10 | 4 | 8 | 9 | 18 | 24 | 45 | 35 | 19 | 22 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 522 | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | |
Cash Fr. Inv. | -369 | -689 | -218 | -149 | -135 | -165 | -510 | -521 | -855 | -725 | |
Cash Fr. Finan. | -136 | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | |
Net Change | 17 | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 428 | 588 | |
Cash & Cash Eqvt | 74 | 104 | 169 | 143 | 218 | 371 | 295 | 559 | 991 | 1,579 |
Fri, 29 Mar 2024
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report Voting Results of the Postal Ballot alongwith Scrutinizer Report |
Fri, 29 Mar 2024
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot Voting Results & Scrutinizer Report |
Wed, 27 Mar 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release w.r.t. Technology Transfer for development of an anti-cancer biosimilar for global market |
Thu, 28 Mar 2024 |
Higher Delivery Quantity |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |
Close Crossing Last Week High |
Opening at Low |